Japanese Insurance Stock News

TSE:4568
TSE:4568Pharmaceuticals

A Look At Daiichi Sankyo (TSE:4568) Valuation After DATROWAY Priority Review Milestone

Daiichi Sankyo Company (TSE:4568) shares are in focus after the U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for DATROWAY in advanced triple negative breast cancer. See our latest analysis for Daiichi Sankyo Company. At a share price of ¥2,952.0, Daiichi Sankyo’s 1 day share price return of 2.89% and 7 day gain of 1.22% contrast with a 30 day share price decline of 16.66% and a 1 year total shareholder return of 19.19% in the red. This suggests...
TSE:7733
TSE:7733Medical Equipment

Olympus (TSE:7733) Valuation Check As New HR And Manufacturing Leaders Join The MedTech Push

Olympus (TSE:7733) has reshaped its senior leadership by appointing Simone Berger as Chief Human Resources Officer and David Shan as Chief Manufacturing and Supply Officer, effective April 1, 2026, following a board meeting that reviewed executive roles. See our latest analysis for Olympus. The executive reshuffle comes after a softer patch for the stock, with a 30 day share price return decline of 7.05% and a 1 year total shareholder return decline of 11.96%, while the recent 7 day share...
TSE:8031
TSE:8031Trade Distributors

Mitsui (TSE:8031) Valuation Check After Buffett Spotlight And Updated Earnings Guidance

Why Mitsui’s latest earnings and Buffett link are back in focus Mitsui (TSE:8031) is back on investor watchlists after renewed attention on Warren Buffett’s Japanese trading house holdings, combined with the company’s latest nine month earnings and fresh full year profit guidance. See our latest analysis for Mitsui. The share price has moved to ¥5,364 after a 3.63% 1 day share price return and 35.22% 90 day share price return. The 1 year total shareholder return of 96.65% suggests strong...
TSE:2413
TSE:2413Healthcare Services

Do M3’s (TSE:2413) Higher EPS Figures Hint At A Deeper Profitability Shift?

M3, Inc. has reported past earnings results for the nine months ended December 31, 2025, with sales of ¥264,395 million and net income of ¥45,237 million, both higher than a year earlier. Earnings per share from continuing operations also increased on both a basic and diluted basis, pointing to improved profitability across the existing business. Next, we will examine how this stronger profitability profile shapes M3’s investment narrative, particularly the implications of higher earnings...